Tuesday’s Keynote Series presentations will examine chronic obstructive pulmonary disease (COPD) and G-protein coupled receptor (GPCR) signaling. Presenters on Wednesday will cover biomarkers for precision medicine in asthma and acute respiratory distress syndrome (ARDS). The lectures will be given concurrently from 8 to 8:45 a.m.
Tuesday
Bartolome R. Celli, MD
The Changing Natural Course of COPD
Moscone Center, Room 134 (North Building, Lower Level)
Bartolome R. Celli, MD, physician at Brigham and Women’s Hospital, and professor of medicine at Harvard Medical School, Boston, Massachusetts
Structural Insights Into GPCR Signaling: Implications for Drug Discovery
Moscone Center, Room 135 (North Building, Lower Level)
Brian K. Kobilka, MD, Nobel laureate; Helene Irwin Fagan Chair in Cardiology, and professor of chemical and systems biology at the Stanford School of Medicine, California
Brian K. Kobilka, MD
The Changing Natural Course of COPD (K5) is supported by educational grants from AstraZeneca LP and GlaxoSmithKline.
Structural Insights Into GPCR Signaling: Implications for Drug Discovery (K6) is supported by educational grants from AstraZeneca LP, Genentech, GlaxoSmithKline, Meda Pharmaceuticals, Inc., and Teva Pharmaceuticals.
Wednesday
Serpil C. Erzurum, MD
Biomarkers for Precision Medicine in Asthma
Moscone Center, Room 134 (North Building, Lower Level)
Serpil C. Erzurum, MD, chair of the Department of Pathobiology, joint staff with the Respiratory Institute, and the Alfred Lerner Memorial Chair in Innovative Biomedical Research at the Cleveland Clinic, Ohio
ARDS: Mechanisms and Professional Societies
Moscone Center, Room 135 (North Building, Lower Level)
Brian Kavanagh, MD, chair of the Department of Anesthesia at the University of Toronto, the Dr. Geoffrey Barker Chair in Critical Care Medicine at the Hospital for Sick Children and the University of Toronto, and research director of the Department of Critical Care Medicine at the Hospital for Sick Children, Toronto, Ontario, Canada
Brian Kavanagh, MD
Biomarkers for Precision Medicine in Asthma (K7) is supported by educational grants from AstraZeneca LP, Genentech, GlaxoSmithKline, Meda Pharmaceuticals, Inc., Sanofi US and Regeneron Pharmaceuticals, and Teva Pharmaceuticals.